false
Hamburger Menu
Catalog
IASLC Lung Cancer News (ILCN), March 2022
IASLC Lung Cancer News (ILCN), March 2022
ILCN | English | 2022
Create Account
Availability
On-Demand
Cost
$0.00
Credit Offered
No Credit Offered
IASLC Lung Cancer News (ILCN), March 2022
Table of Contents
The FDA Explained: An Interview with Dr. Harpreet Singh
A New Standard of Care in EGFR-Positive NSCLC Unresponsive to TKIs?
The OncoKB Precision Oncology Knowledge Base: A Q&A with Dr. Debyani Chakravarty
Targeting Angiogenesis in Mesothelioma: Insights From MAPS and RAMES
US FDA greenlights nivolumab for use before surgery for NSCLC
Low-Dose CT, ctDNA May Partner for Lung Cancer Detection
Award Lecture Highlights Tumor Evolution Through Liquid Biopsy
Patient Perspective: Anxiety Follows Abrupt Departure From Clinical Trial
Determining the Most Effective Chemotherapy Regimen in Patients With Advanced KRAS-Mutated NSCLC: the NVALT22 study
Novel Targets and Therapies: KEAP1- and NFE2L2-Mutant Squamous Cell Lung Cancer
Management of Recurrences after Stereotactic Ablative Radiotherapy for Operable Early-Stage Non-Small Cell Lung Cancer
Role of Liquid Biopsy in the Clinic Growing
Need for Molecular Nursing Increasing
About ILCN
IASLC Lung Cancer News (ILCN) is the offical news source of the only global association dedicated to the multidisciplinary study of lung cancer, published bimonthly by the International Association for the Study of Lung Cancer (IASLC).
Click here to link to
Submission Guidelines
.
×
IASLC Lung Cancer News (ILCN), March 2022 Course List
Login
User Login
Continue with Google
OR
Email
Password
Logging In…
Create Account
Forgot Password
×
Please select your language
1
English